Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
نویسندگان
چکیده
منابع مشابه
FOXO1A is a target for HER2-overexpressing breast tumors.
Trastuzumab treatment has improved the overall survival of HER2-overexpressing breast cancer patients. However, many of these patients will eventually become resistant to treatment. The mechanisms that contribute to resistance to trastuzumab are unknown. In this study, we tested the hypothesis that targeting of the FKHR transcription factor FOXO1A in HER2-overexpressing breast tumor cells can o...
متن کاملMolecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
The epidermal growth factor receptor 2 (HER2) is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast cancers. Trastuzumab is a humanized monoclonal antibody that targets HER2. The majority of patients with metastatic breast cancer initially respond to trastuzumab, however, within 1 year of treatment disease progresses. Several molecular mechanisms have been described as cont...
متن کاملNovel approaches to target HER2-positive breast cancer: trastuzumab emtansine
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast carcinomas. Prior to the development of targeted therapies, HER2-positive breast cancer was associated with more aggressive disease and poor prognosis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that results from the combination of trastuzumab and DM1, a derivative of the antimicrotubule agent...
متن کاملCancer stem cell hypothesis and trastuzumab in HER2-negative tumors.
T rastuzumab (herceptin) is approved for the treatment of breast cancer patients whose tumors express a high level of the drug's target her2/neu. yet at least two retrospective analyses of prospec tive trials suggest the drug may also improve survival in women with early breast cancer whose tumors do not overexpress her2/ neu. A plausible mechanism for those con troversial observations has be...
متن کاملWeekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
We evaluated the efficacy and safety of weekly paclitaxel plus trastuzumab as first-line chemotherapy in women with HER2-overexpressing metastatic breast cancer (MBC), and we investigated the prognostic factors including magnitude of HER2/neu amplification in this population. We analyzed 54 patients with HER2-overexpressing MBC that were treated with weekly paclitaxel plus trastuzumab as first-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nanomaterials
سال: 2019
ISSN: 2079-4991
DOI: 10.3390/nano9070948